Peter A. Thompson - 20 Jun 2024 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
Director
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Issuer symbol
SPRY
Transactions as of
20 Jun 2024
Transactions value $
$0
Form type
4
Filing time
24 Jun 2024, 17:00:11 UTC
Previous filing
17 Jun 2024
Next filing
23 Aug 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (right to buy) Award $0 +40K $0.00 40K 20 Jun 2024 Common Stock 40K $7.73 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option will vest in full on the earlier of June 20, 2025 or the date of the Issuer's 2025 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
F2 Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP.